NCT06491056Recruiting
Prospective Asian Multicenter Prostate Cancer Focal Therapy Study (ProAMFocal)
Prospective Multicenter Asian Observational Study of Oncological and Functional Outcomes After Focal Therapy of Prostate Cancer
Source: ClinicalTrials.gov · Last updated 8 Jul 2024 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
This is a multicenter observational study of patients undergoing focal therapy for prostate cancer in Asia
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 500 (estimated)
- First submitted
- 3 Jul 2023
- Start date
- 6 May 2023
- Primary completion date
- 6 May 2028
- Lead sponsor
- Singapore General Hospital
- Diseases
- Prostate cancer
- NCT number
- NCT06491056
What you commit to
- Study type: Observational
- Planned participants: 500
- From 6 May 2023 to the primary completion date, 6 May 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Extra-prostatic Extension on multi parametric magnetic resonance imaging (mpMRI); capsular contact is permitted
Who the study is looking for
- Prostate Adenocarcinoma
- Maximum Gleason score 4+4
- Maximum cancer volume 1.5 ml (up to 2 lesions) or 3 ml (single lesion)
- Maximum Prostate Specific Antigen (PSA) level 15 ng/dl
- Maximum clinical stage T2c
- American Society of Anesthesiologist Criteria 2 or less
Age in the registry: 40 years to 85 years · Sex: Male · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Singapore General Hospital Coordinator of this site? Confirm its status | Singapore | Singapore | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.